To explore new strategies for joint treatment of tumor immunology, an expert seminar was held in Hebei.

For different immunosypeeds in tumor therapy, different treatment measures can be used, such as clinically used PD-1 combined anti-vascular therapy, car-t therapy, drug-carrying vesicles to treat tumor technology and other tumor bioimmune treatment methods. Recently, the first meeting of the Hebei Cancer Association's Professional Committee on Cancer Bioimmune Therapy in 2020 and the seminar of technical experts on new tumor bioimmune therapy were held, and the experts discussed the clinical status and future development trend of tumor bioimmune therapy in Hebei Province.
2014, an estimated 174,000 new cases of malignant tumors occurred in Hebei province, or an average of one person per three minutes, according to the annual report on cancer registration in Hebei Province. The morbidity rate is basically the same as the national average, but the mortality rate is slightly higher than the national average.
Hebei Medical University Vice President, Hebei Medical University Fourth Hospital Party Secretary, Hebei Province Cancer Research Institute Director Professor Shan Baoen said that most of the cancer treatment methods are mainly aimed at the tumor itself, not from the overall design of treatment strategies, and our body's immune system is a special anti-tumor physiological system, should play this system to treat tumors, but professional immunotherapy disciplines should be based on the theoretical basis of immunology to regulate treatment strategies.
Professor Wang Zhiyu, Director of Oncology Immunology Department of The Fourth Hospital of Hebei Medical University, pointed out that in order to enrich the treatment of tumors in Hebei and improve the level of cancer treatment, we have been trying to find a variety of combination therapy strategies, such as immuno-combined chemotherapy, immuno-combined radiotherapy, immuno-targeted therapy, double-free combination therapy, drug-carrying vesicles to treat tumor technology. Among them, Chinese scientists pioneered the drug-carrying vesicle treatment tumor technology is currently the fastest-growing clinical transformation of innovative technology, it will be biological chemotherapy and immunotherapy combined, using targeted precision effects combined with chemotherapy, short-term killing of tumor cells for rapid relief, while activating specific anti-tumor immunity, to produce long-lasting tumor surveillance to prevent tumor recurrence, and thus improve the quality of patient survival.
In addition, the hospital also carried out a number of new cancer immunotherapy clinical trials, such as "immune cell combined chemotherapy treatment of lung scale cancer multi-center clinical research and new strategy research and development" (National 973 project), "drug-carrying cystic chest perfusion combined systemic treatment program for the treatment of malignant thoracic fluid multi-center, randomized controlled clinical research", and actively explore new cancer immunological technology, new therapy safety and effectiveness issues, in order to achieve clinical transformation to do a better job of pre-treatment for patients in Hebei region.
.